SequelSEC

MADRIGAL PHARMACEUTICALS, INC. MDGL

Pharmaceutical Preparations · CIK 0001157601 · Fiscal year ends 1231

Revenue
$958.40M
Fiscal year ended 2025-12-31
Operating income
-$300.10M
Fiscal year ended 2025-12-31
Free cash flow
-$190.02M
Fiscal year ended 2025-12-31

MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported revenue of $958.40M and net income of -$288.28M for the fiscal year ended 2025-12-31. This page shows 9 annual periods of income statement, balance sheet and cash flow figures normalized from MADRIGAL PHARMACEUTICALS, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

MADRIGAL PHARMACEUTICALS, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-31
Revenue$958.40M$180.13M$0$0$0$0$0$0$0
Cost of revenueUnavailable$6.23M$0$0UnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailable$0UnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$300.10M-$497.88M-$380.50M-$293.57M-$242.48M-$206.67M-$94.97M-$40.68M-$32.06M
Net income-$288.28M-$465.89M-$373.63M-$295.35M-$241.85M-$202.24M-$83.95M-$32.81M-$31.15M
Research & developmentUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Weighted-average diluted sharesshares 28.41Mshares 26.91Mshares 21.56Mshares 17.14Mshares 16.54Mshares 15.45MUnavailableUnavailableUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expense$0$0$0$0$0$0$0$0Unavailable
Diluted EPS$-10.15$-17.31$-17.33$-17.23$-14.63$-13.09UnavailableUnavailableUnavailable
Selling, general & administrative$813.83M$435.06M$108.15M$48.13MUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrativeUnavailableUnavailable$108.15M$48.13M$37.32M$21.86M$22.65M$15.29M$7.67M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

MADRIGAL PHARMACEUTICALS, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-31
Cash & equivalents$198.69M$100.02M$99.92M$331.55M$36.27M$54.00M$46.70M$57.38M$148.63M
Total assets$1.26B$1.04B$640.55M$362.57M$273.33M$287.00M$442.06M$485.43M$192.31M
Current assets$1.25B$1.03B$637.28M$361.37M$271.68M$285.16M$440.20M$485.20M$192.01M
Total liabilities$656.90M$287.86M$235.21M$165.18M$77.22M$47.02M$25.49M$8.44M$10.05M
Current liabilities$310.29M$169.28M$118.55M$115.89M$76.84M$46.56M$25.13M$8.44M$10.05M
Total equity incl. NCI$602.69M$754.38M$405.33M$197.39M$196.11M$239.97M$416.56M$476.98M$182.26M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$74.84M$34.07M$0UnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivable$134.48M$53.82M$0UnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt$339.88M$117.57M$115.48M$49.29M$0UnavailableUnavailableUnavailableUnavailable
Accounts payable$48.88M$43.60M$28.04M$23.83M$21.38M$1.02M$1.18M$2.49M$1.93M

Cash flow

MADRIGAL PHARMACEUTICALS, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-31
Operating cash flow-$189.55M-$455.57M-$324.23M-$224.86M-$183.92M-$157.56M-$41.62M-$25.51M-$22.32M
Capital expenditures$467.00K$1.46M$1.48M$217.00K$209.00K$334.00K$172.00K$22.00K$125.00K
Investing cash flow$32.32M-$274.39M-$502.52M$206.69M-$5.06M$159.78M$30.71M-$380.08M-$22.01M
Financing cash flow$255.98M$735.06M$595.12M$313.45M$171.24M$5.09M$235.00K$314.34M$173.80M
Net change in cash$98.76M$5.10M-$231.63M$295.28M-$17.74MUnavailableUnavailableUnavailable$129.48M
Stock-based compensation$98.13M$79.88M$49.74M$31.62M$26.87M$20.73M$22.76M$13.49M$3.25M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$1.51M$1.10M$527.00K$467.00K$405.00K$471.00K$112.00K$96.00K$77.00K

Derived

MADRIGAL PHARMACEUTICALS, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-31
Free cash flow-$190.02M-$457.03M-$325.71M-$225.07M-$184.13M-$157.90M-$41.80M-$25.53M-$22.44M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating margin-31.3%-276.4%UnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF margin-19.8%-253.7%UnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenue10.2%44.3%UnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio4.01x6.10x5.38x3.12x3.54x6.13x17.52x57.46x19.10x
Revenue YoY growth432.1%UnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net margin-30.1%-258.6%UnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenue0.0%0.8%UnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equity0.56xUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open MDGL in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-07-30View SEC filing
10-Q · Filed 2026-05-06View SEC filing
10-K · Filed 2026-02-19View SEC filing
10-Q · Filed 2025-11-04View SEC filing
10-Q · Filed 2025-08-05View SEC filing
10-Q · Filed 2025-05-01View SEC filing

Companies in the same industry

Reconciliation checks needing review

2 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2024-12-31

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2023-12-31

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.